

Health Hazards and Nitrous Oxide: A Time for Reappraisal

John A. Yagiela, DDS, PhD

Section of Oral Biology, School of Dentistry,
and Department of Anesthesiology, School of Medicine,
University of California Los Angeles, Los Angeles, California

Recent adoption by the American Conference of Governmental Industrial Hygienists of a Threshold Limit Value of 50 ppm for an 8-hour average exposure to nitrous oxide (N₂O) increases the likelihood for its regulation by state and federal occupational health agencies. This review outlines current information on the health risks of N₂O inhalation to provide a basis from which safe and reasonably attainable exposure limits can be proposed. Although N₂O was for many years believed to have no toxicity other than that associated with its anesthetic action, bone marrow depression in patients administered N₂O for extended periods of time and neurological abnormalities in health care workers who inhaled N₂O recreationally have disproved this notion. Retrospective surveys of dental and medical personnel have also linked occupational exposure to N₂O with a number of health problems and reproductive derangements. Nitrous oxide reacts with the reduced form of vitamin B₁₂, thereby inhibiting the action of methionine synthase, an enzyme that indirectly supports methylation reactions and nucleic acid synthesis. Many, if not all, of the nonanesthetic-related adverse effects of N₂O may be ascribed to this action. Animal and human studies indicate that the toxic effects of N₂O are concentration- and time-dependent. It is suggested that a time-weighted average of 100 ppm for an 8-hour workday and/or a time-weighted average of 400 ppm per anesthetic administration would provide adequate protection of dental personnel and be achievable with existing pollution control methods.

Over a decade has passed since a battery of reports alerted the dental profession to the potential health hazards of nitrous oxide (N₂O) in dentistry. In May 1977, the National Institute for Occupational Safety and Health (NIOSH) released its criteria document, *Occupational Exposure to Waste Anesthetic Gases and Vapors*, which recommended a maximum permissible time-weighted average exposure of 25 ppm N₂O per anesthetic administration for all health care workers.¹ In October of that year, in an issue of the *Journal of the American Dental Association* largely devoted to the topic of trace inhalation anesthetics in the dental office, the ADA Ad Hoc Committee on Trace Anesthetics as a Potential Health Hazard in Dentistry published its position paper.² Although the Committee had serious reservations regarding the research available then, it recognized the potential for a health hazard and strongly urged that, "every effort should be made to reduce, by presently existing technology, the trace concentration of anesthetic/sedative agents in the dental environment." In 1978, publication of two seminal papers would broaden concerns and lead the way to a possible understanding of the basis for adverse responses to N₂O exposure. In one, Layzer et al reviewed three health workers who developed disabling peripheral neuropathy following habitual abuse of N₂O.³ In the other, Amess et al found that in patients undergoing open heart surgery N₂O could cause hematopoietic changes indicative of pernicious anemia.⁴ Subsequent important landmarks included the large-scale epidemiologic study of occupational disease in the dental profession and chronic exposure to N₂O by Cohen et al⁵ and elucidation of the effects of N₂O on vitamin B₁₂ biochemistry.^{6,7}

The year 1978 also witnessed publication of two comprehensive and critical reviews of the scientific evidence that led to the NIOSH report.^{8,9} These reviews served two purposes: (1) they presented the findings of the various studies in a form that facilitated comparison and evaluation; and (2) they pointed out methodological limitations that should caution the reader from making decisions or judgments based on insufficient or erroneous information. Perhaps in recognition of these shortcomings, the Occupational Safety and Health Administration (OSHA) de-

Received September 12, 1990; accepted for publication February 15, 1991.

Address correspondence to Dr. John A. Yagiela, UCLA School of Dentistry, Center for the Health Sciences, Los Angeles, CA 90024.

© 1991 by the American Dental Society of Anesthesiology

ISSN 0003-3006/91/\$3.50

Table 1. Changes in Peripheral Blood in Relation to Drugs Used in 13 Patients with Severe Tetanus. (From Lassen et al¹¹)

Treatment	Patients With Complications*	Patients Without Complications
Chloral hydrate	3	7
Pentobarbital	5	5
Meperidine	0	1
Tubocurarine	3	0
Bromethol	0	1
Continuous N ₂ O	6	0

* Granulocytopenia and/or thrombocytopenia.

NOTE: All patients also received antibiotics, but these were not tabulated.

ferred establishing an official maximal exposure for N₂O. There are indications, however, that this restraint is about to end.

Recently, the American Conference of Governmental Industrial Hygienists (ACGIH) set a Threshold Limit Value of 50 ppm for an 8-hour average exposure to N₂O.¹⁰ Although this organization has no regulatory power, OSHA historically has followed its recommendations. Under the rubric of the General Duty Clause of the 1970 Occupational Health and Safety Act, which requires employers to protect employees from recognized hazards in the workplace, OSHA inspectors are empowered to cite dentists for failure to equip N₂O delivery systems with scavenging circuits. It appears only a matter of time before a Permissible Exposure Limit of N₂O will be proposed.


Given this regulatory climate, a balanced understanding of the salient facts concerning health hazards of N₂O and recommendations and procedures for limiting occupational exposure becomes critically important.

BIOCHEMICAL BASIS FOR INJURY

Historically, N₂O was thought to be chemically inert in the human body. Adverse reactions to N₂O were attributed to hypoxia (from failure to administer sufficient oxygen with the anesthetic) or to known risks of general anesthesia (eg, respiratory or cardiac complications). The first hint the N₂O had toxic potential unrelated to anesthesia or hypoxia per se was offered by Lassen et al, who noted in a *Lancet* article in 1956¹¹ that severe bone marrow depression occurred after prolonged N₂O anesthesia in patients being treated for tetanus. In fact, two patients died as a consequence of septicemia that developed after severe leukopenia. A study of 13 patients indicated that the only consistent correlate between tetanus patients who exhibited hematologic complications and those who did not was the administration of N₂O (Table 1). Subsequent reports published shortly thereafter confirmed this association, but no explanation for the effect was given.

Nitrous Oxide and Vitamin B₁₂

Banks and co-workers reported in 1968¹² that N₂O could oxidize nonenzymatically the cobalt atom in reduced vitamin B₁₂ (cob[I]alamin) as follows:



This discovery had biological implications because only the monovalent (reduced) form of vitamin B₁₂ is active in vivo. However, buried among a number of similar observations of gases and transitional metal complexes, the reaction was not recognized as important clinically until Amess and associates made the connection between N₂O and pernicious anemia.⁴

Amess et al found that patients exposed to 50% N₂O for 6 to 24 hours developed megaloblastic changes in bone marrow cells and that these changes were accompanied by increases in the deoxyuridine suppression test, which measures in vitro the ability of deoxyuridine (dU) to compete with ³H-thymidine for incorporation into bone marrow DNA:


$$\text{dU suppression} = \frac{^3\text{H-DNA in presence of dU}}{^3\text{H-DNA in absence of dU}} \times 100(\%) \quad (2)$$

A high dU suppression score indicates impaired conversion of dU monophosphate to thymidine monophosphate, a process ultimately dependent on active vitamin B₁₂. In these patients, as in patients with pernicious anemia, dU suppression scores were increased. A variety of studies quickly followed substantiating the fact that N₂O can inactivate vitamin B₁₂ and therefore cause biochemical derangements similar to those seen in pernicious anemia.

Vitamin B₁₂ is essential for the function of three enzymes in mammals: (1) methionine synthase (methionine synthetase), which catalyzes the synthesis of methionine and tetrahydrofolate from homocysteine and 5-methyltetrahydrofolate; (2) methylmalonyl-CoA mutase, which supports the transformation of methylmalonyl-CoA to succinyl-CoA; and (3) leucine 2,3-aminomutase, which permits the interconversion of leucine and β -leucine. The synthase and mutase enzymes differ in the form of the vitamin B₁₂ cofactor used and in their susceptibility to inactivation by N₂O. Methionine synthase uses methylcobalamin and is rapidly affected by N₂O. The mutase enzyme relies on 5-deoxy-adenosylcobalamin and is essentially immune to direct inactivation. Since the Co⁺ in 5-deoxyadenosylcobalamin is believed to be subject to oxidation just as it is in methylcobalamin, it is postulated that the mutase may work equally well with oxidized cofactor.¹³ Because the vitamin B₁₂-dependent aminomutase enzyme is a fairly recent discovery,¹⁴ it has not been investigated concerning

N_2O . Its reliance on 5-deoxyadenosylcobalamin as the cofactor implies, however, that it may be resistant to N_2O .

Exactly how N_2O inactivates methionine synthase is unknown. Recent biochemical studies suggest that a variant of the reaction described by Banks et al¹² might lead to both vitamin B₁₂ oxidation and enzyme damage. In this reaction:



a hydroxyl radical is generated, which is highly reactive and could proceed to alter chemically the adjacent synthase enzyme. In support of this proposal is the finding in mice that administration of a hydroxyl radical scavenger impedes destruction of methionine synthase by N_2O .¹⁵

Metabolic Derangements

A variety of metabolic disturbances are caused by a decline in methionine synthase activity. As can be deduced from Figure 1, the biosynthesis of methionine, tetrahydrofolate, and thymidine monophosphate is diminished.¹⁶ Derivatives of tetrahydrofolate (ie, 10-formyl- and 5,10-methenyltetrahydrofolate) essential to the formation of purine nucleotides are also affected, and DNA synthesis is impaired. A number of additional single-carbon transfer reactions dependent on S-adenosylmethionine and tetrahydrofolate analogues is likewise affected.

None of the substrates illustrated is totally dependent on methionine synthase activity for its existence, at least in the short term. Methionine is a natural constituent of the diet, and it can also be synthesized by way of the so-called betaine pathway; thymidine and purines are also dietary constituents and can be recycled through salvage pathways for reincorporation into nucleic acids; interconversion of folate analogues (with the notable exception of 5-methyltetrahydrofolate) can ameliorate temporarily the loss of tetrahydrofolate.

Clinically evident (but nonhypoxic or anesthesia-related) changes in response to N_2O inhalation depend on a variety of factors, many of which are co-dependent. These factors include:

- (1) the intensity, duration, and pattern of exposure to N_2O ;
- (2) the degree of inactivation of methionine synthase and the time course of recovery;
- (3) the extent to which body stores and dietary intake (including vitamin and/or amino acid supplements) offset the biochemical block caused by N_2O ;
- (4) the sensitivity of important biochemical pathways to substrate decrements; and
- (5) the sensitivity of tissues to alterations by the affected biochemical pathways.




Figure 1. Biochemistry of methionine synthase-associated reactions (large arrow indicates block by N_2O). Major pathways involving folate analogues that support DNA synthesis are included. Abbreviations: 5-CH₃-H₄ Folate, 5-methyltetrahydrofolate; H₄ Folate, tetrahydrofolate; 5,10-CH₂-H₄ Folate, 5,10-methylenetetrahydrofolate; H₂ Folate, dihydrofolate; 5,10-CH=H₄ Folate, 5,10-methenyltetrahydrofolate; 10-CHO-H₄ Folate, 5,10-formyltetrahydrofolate; SAM, S-adenosylmethionine; -CH₃, methylation reactions; Active Formate, methylthioribose phosphate; dUMP, deoxyridine monophosphate; dTMP, thymidine monophosphate.

Factor 1 is under the control of the clinician, and the rest of this article will concentrate on how and to what extent exposure should be controlled. Factor 3 is also potentially modifiable, and the use of agents to prevent "biochemical" toxicity from N_2O will be mentioned. One caveat should be raised at this time. Although the biochemical basis for toxicity is strongly supported, it remains possible that other aspects of N_2O pharmacology may contribute to health hazards associated with exposure to the gas.¹⁷ These include the formation of toxic substances during the metabolism of N_2O by enteric bacteria¹⁸ and interaction with the endogenous opioid system leading to such physiological disturbances as decreased release of luteinizing hormone releasing hormone.¹⁹

TOXICITY AND CLINICAL EXPOSURE

Evidence is overwhelming that prolonged exposure to clinical concentrations of N_2O inhibits cellular proliferation of the formed elements of blood and can lead to megaloblastic anemia, leukopenia, and thrombocytopenia.^{4,7,13} As shown in Figure 2, these hematopoietic changes are preceded by disturbances in thymidylate metabolism as measured by the dU suppression test.⁷ Inhibition of




Figure 2. Hematopoietic toxicity of N_2O in humans. Mean dU suppression scores in 5 surgery patients receiving 50% N_2O for 24 hours (\blacktriangle) and two patients receiving etomidate (\triangle) are shown along with the mean percentage of hypersegmented neutrophils in peripheral blood (less 1 N_2O patient; \bullet = N_2O , \circ = etomidate). Abnormal thymidylate synthesis in the N_2O group presages an altered hematopoiesis. Data from Skacel et al.⁷

methionine synthase is an expected prerequisite for depression of thymidylate synthesis by N_2O . Whereas rats and mice are not susceptible to megaloblastic anemia during vitamin B_{12} deficiency, they are even more responsive^{20,21} than humans²² with respect to inhibition of methionine synthesis (Figure 3).

Biochemical recovery from exposure to clinical concentrations of N_2O does not begin until inhalation of the gas is terminated. Afterward, the induced derangements subside in association with the formation of active holoenzyme. Data (eg, as in Figure 2) suggest that several days may be required for full return of methionine synthase activity.^{6,7} Slow reversal of N_2O toxicity raises the possibility that repeated exposures may lead to a cumulative effect. Indeed, Nunn et al have reported that a patient receiving 50% N_2O for 15 min 3 times a day for 24 days developed megaloblastic changes and increased dU suppression values.²³ Recovery rate may also depend on the health of the individual. Patients who can return immediately to a normal diet might hasten recovery by replacing some of the lost essential metabolites. At the other extreme, gravely ill patients are likely to be more seriously affected by the same degree of exposure to N_2O and take longer to recover.²⁴

Several investigators have shown that the hematopoietic changes induced by N_2O can be reversed or even prevented by administration of appropriate agents. Vitamin B_{12} given after N_2O can at least partially offset the effect of N_2O as measured by the dU suppression test.^{4,7} Folic acid (formyltetrahydrofolate) and several analogues (eg, tetrahydrofolate) but not 5-methyltetrahydrofo-

late can reverse or even prevent disturbances in nucleic acid synthesis and thus the hematologic sequelae to N_2O .^{7,25,26} However, as in the neuromyopathy of pernicious anemia, folate derivatives have little influence on reactions dependent on methionine synthesis.

The clinical implications of the interaction between N_2O and vitamin B_{12} have been reviewed by Nunn and Chanarin.¹³ Even though inactivation of methionine synthase must occur routinely, disturbances in cellular proliferation are generally quite minor. Nevertheless, continuous administration beyond 24 hours, or repeated administration more frequently than once every 3 to 4 days, will result in leukopenia and megaloblastic changes. Patients who have serious pre-existing hematologic disturbances or who are morbidly ill may have unique sensitivity to N_2O , but data are too scanty to make any particular recommendation for these patients.

Spontaneous abortion and fetotoxicity are important concerns regarding chronic exposure to N_2O in the workplace. It is not known if these concerns should also apply to the clinical use of N_2O . Crawford and Lewis²⁷ reviewed 433 operations in which N_2O was administered to women in the first two trimesters of pregnancy and failed to uncover a single instance in which N_2O caused any deleterious effect. Most of these anesthetics involved exposures under 30 min, however, and until this issue is explored more fully, the potential of N_2O for inhibiting DNA synthesis must be considered in any decision to use N_2O on a pregnant patient, especially when prolonged or multiple administrations are planned. Similarly, the influence of N_2O on leukocyte proliferation raises some concern over

Figure 3. Inactivation of hepatic methionine synthase in rats given 50% N_2O ,²⁰ mice exposed to 80% N_2O ,²¹ and humans administered 50% to 70% N_2O .²² Exposure to N_2O is calculated as the product of the concentration and the time.¹³




Table 2. Neurological Symptoms in 15 Patients with N₂O Myeloneuropathy. (From Layzer³³)

Symptom	Patients With Symptoms Initially	Patients With Symptoms Later
Lhermitte's sign	0	12
Numbness, paresthesia, or clumsiness of hands	7	13
Numbness or paresthesia in legs	7	15
Numbness of trunk	0	10
Impairment of equilibrium or gait	3	12
Inability to walk unassisted	0	7
Impotence	0	7
Impairment of sphincter control	0	4
Altered mood or difficulty in thinking	0	7
Relapsing course	—	6
Inability to work	—	10

its use in patients with severe infections. Although short-term (less than 6 hours) exposure probably is without potential danger insofar as affecting white cell counts is concerned,²⁵ Nunn and O'Morain have found that N₂O impairs mobilization of neutrophils from peripheral storage sites.²⁸ Nitrous oxide also inhibits neutrophil chemotaxis, but this effect is shared by other inhalation anesthetics and seems unrelated to a specific toxic effect of N₂O. Together, these data suggest that N₂O would be a suboptimal choice as a sedative/analgesic for infected patients requiring protracted or repeated anesthesia.

TOXICITY AND DRUG ABUSE

By modern definition, Humphrey Davy was the first abuser of N₂O. In his treatise on N₂O,²⁹ Davy described both the euphoric and the addicting potential of laughing gas:

"The desire of some individuals acquainted with the pleasure of nitrous oxide for the gas has been so strong as to induce them to breathe with eagerness, the air remaining in the bags after the respiration of others."

He also described symptoms of chronic toxicity from overindulgence:

"During the last week in which I breathed it uniformly, I imagined that I had increased sensibility of touch: my fingers were pained by anything rough . . . My bodily strength was rather diminished than increased."

N₂O began as a "social drug," and it is still used in that manner today. Occasional reports^{30,31} of individuals being asphyxiated by improper self-administration have not dampened enthusiasm for N₂O as a safe drug available in pure form in medical gas cylinders or as a propellant for whipping cream.³²

The clinical report by Layzer et al³ describing the delayed development of a distinctive neurologic syndrome

in 3 health care workers who used N₂O recreationally engendered communications of similar reactions, and Layzer was able to compile data quickly on 15 individuals with the same syndrome.³³ Only two of this group denied N₂O abuse; both of these were oral surgeons who were heavily exposed to the gas in their professional practice. Table 2 lists the major symptoms reported by the 15 patients. Initial symptoms consisted of numbness or parasthesia of the limbs. With continued abuse, sensory symptoms would worsen and motor impairment become manifest. Concomitant neurologic signs (Table 3) included evidence of muscle weakness, impaired sensation, and altered reflexes. Cessation of N₂O inhalation led to improvement of the myeloneuropathy, but residual deficits indicative of potentially permanent neural injury were noted in approximately half of the patients.

Although patients with N₂O myeloneuropathy generally have had normal serum folate and vitamin B₁₂ concentrations at time of testing, the similarity of signs and symptoms with those of vitamin B₁₂ deficiency naturally led to investigations of a linkage between the two conditions. The monkey has proved especially useful as a model. Monkeys self-administer N₂O when the gas is the sole reinforcer of behavior.³⁴ Moreover, exposure to 15% N₂O for 2 weeks causes ataxia, uncoordination, and degeneration of the spinal cord, effects that can be largely prevented by providing methionine supplementation in the diet.³⁵ Methionine has also been shown to reverse the neuropathy caused by vitamin B₁₂ deprivation or N₂O administration in the pig³⁶ and fruit bat.³⁷ Interference with methionine metabolism may impair transmethylation reactions³⁶ and/or nucleic acid synthesis³⁸ vital to neuronal health.

The easy access to N₂O and a general lack of strict control of its use makes N₂O a simple substance to abuse for health professionals, particularly those in the dental profession. A questionnaire distributed to dental and medical students at an eastern university revealed that 16% of the 524 respondents had used N₂O in a social setting.³⁹

Table 3. Neurologic Signs in 15 Patients with N₂O Myeloneuropathy During Active Stage of Illness and Recovery. (From Layzer³)

Sign	Patients During Active Stage	Patient With Residual Deficits
Romberg sign or ataxic gait	11	4
Muscle weakness in distal legs	7	5
Muscle weakness in proximal legs	3	1
Muscle weakness in arms	4	0
Impaired sense of touch, vibration, or position	15	8
Diminished or absent knee jerks	8	3
Increased knee jerks	6	3
Diminished or absent ankle jerks	12	5
Increased ankle jerks	3	1
Extensor plantar reflexes	8	3

Using a questionnaire sent to licensed dentists in West Virginia who graduated from the West Virginia School of Dentistry between 1969 and 1977, Gutmann and Johnsen⁴⁰ found that 51% of the 143 respondents used N₂O regularly in practice. Eight user-dentists reported one or more neurologic symptoms in themselves or their assistants. Three of these respondents identified themselves and were interviewed. In two instances, recreational drug use was uncovered, one involving the dentist, the other involving two assistants. In the third case, the dentist used 50% N₂O on patients routinely (6 to 7 hours daily) without the benefit of scavenging equipment.

Taken together, the findings described in this section reasonably support several conclusions: (1) N₂O is a potential drug of abuse especially targeted to the dental profession; (2) A small percentage of dentists (possibly 1% to 5% of practitioners using N₂O in their offices), and some auxiliary personnel as well, self-administer N₂O, or at least did so during the late 1970s; (3) Repeated exposures can, probably by oxidation of vitamin B₁₂ and inhibition of methionine synthesis, lead to myeloneuropathic disturbances; (4) Although the dangers of N₂O abuse should caution the reader against self-administration, it seems clear that such abuse is not a major public health concern, being overshadowed by more ubiquitous habituations, such as alcoholism and cigarette smoking. As will be mentioned in the next section, a final conclusion that can be drawn is that potential abusers of N₂O should be considered in evaluating survey results of health hazards to trace contamination of inhalation agents.

TOXICITY AND OCCUPATIONAL EXPOSURE

Unquestionably, the primary health concern regarding the use of N₂O in dentistry is the possibility of occupational disease resulting from chronic exposure to trace amounts of gas. The question was first raised by a report in the

Russian literature describing a variety of ailments and an unusual number of miscarriages occurring in anesthesiologists.⁴¹ Since 1967, numerous epidemiologic surveys, animal studies, and other investigations have been conducted in attempts to determine what the true dangers of chronically inhaling low concentrations of anesthetic agents are. Studies that relate directly to N₂O will be reviewed according to the research methodology used.

Retrospective Surveys

The large-scale epidemiologic study by Cohen and co-workers,^{5,42} carried out in conjunction with the American Dental Association, remains the definitive epidemiologic survey of N₂O exposure and related health problems. It was an impressive effort and seemed to avoid major pitfalls (eg, low response rate, multiple anesthetic gases, inequality of control and at-risk groups) that have bedeviled previous studies of this kind.^{8,9} Figures 4 and 5 summarize the statistically significant findings of this investigation of the relationship between N₂O exposure and health and reproductive outcome. Chief among these were a higher incidence of hepatic, renal, and neurologic disorders among exposed personnel, increased spontaneous abortions in chairside assistants and wives of male dentists, and congenital abnormalities in children born to chairside assistants.

Because of the important medical and legal implications of this work, and the possibility that a study of similar magnitude may never be attempted in the future, it deserves careful scrutiny. As with most surveys, the Cohen study was subject to possible respondent bias. The simple fact that inhalation agents were linked to a survey of health problems might have had some effect on respondents. Using recall as the sole source of evidence of adverse events occurring in the previous decade is a serious limitation to this study. Another question regarding the study derives from the fact that 18.7% of the dentists who were





Figure 4. Incidence of health problems in male dentists, and spontaneous abortion in their wives, grouped by exposure to N₂O. Rates were adjusted for age, smoking, and pregnancy history. Light users were dentists with 1 to 2999 hours of exposure the previous decade; heavy users were exposed to 3000+ hours. For spontaneous abortion, light exposure was defined as 1 to 8 hours of exposure per week for the year beginning 6 months before conception. Brackets indicate the standard errors; asterisks reflect significant differences from nonusers ($P \leq 0.05$). Data from Cohen et al.⁵

exposed to N₂O were also exposed to halogenated anesthetics. Although subsequent analysis excluding these individuals from the incidence rates shown in Figures 4 and 5 did not significantly affect outcomes,^{42,43} the simple fact that so many dentists were exposed occupationally to

Figure 5. Incidence of health problems and reproductive abnormalities in female chairside assistants grouped by exposure to N₂O. Rates were adjusted for age, smoking, and pregnancy history. Light users were assistants with 1 to 2999 hours of exposure the previous decade; heavy users were exposed to 3000+ hours. For spontaneous abortion, light exposure was defined as 1 to 8 hours of exposure per week for the year beginning 6 months before conception. Brackets indicate the standard errors; asterisks reflect significant differences from nonusers ($P \leq 0.05$). Data from Cohen et al.⁵



general anesthetics indicates that a high number of oral surgeons and/or hospital dentists were disproportionately included in the user category. Thus, the cohort groups might not have been as similar as one would otherwise have expected. A final concern involves the failure to exclude dentists and chairside assistants who abused N₂O. In Figure 4, for instance, heavy exposure to inhalation anesthetics was associated in male dentists with an 86% increase in neurologic disease. Yet, the total percentage of respondents reporting these disorders rose only 1.66%. This number could easily reflect dentists who inhaled high amounts of N₂O habitually and therefore be spurious with respect to occupational disease and trace gas exposure. Because abusers of N₂O may represent a special subset of respondents, it is possible that other problems, such as liver and kidney derangements, are also linked to this group.

Of all the findings of the Cohen group, the strongest evidence of a health hazard is spontaneous abortion in female chairside assistants. The absolute increase in miscarriage rate is much too high to be ascribed to recreational N₂O inhalation. It is also the most consistent finding in other surveys of this nature.⁴⁴ However, to quote from Tannenbaum and Goldberg, "The consistency of the results may be explained in part by consistency of the methodologic problems, specifically lack of criteria for exposure or outcome, poor survey response rates, selection bias, lack of validation of outcome, recall bias, and lack of control of potentially confounding variables."⁴⁵ It is interesting that two recently published retrospective studies that used examination of public health registries in Sweden⁴⁶ and in Finland⁴⁷ could find no link between working in an operating room and/or being exposed to anesthetic gases and miscarriage or congenital malformation.

Animal Studies

An impressive number of animal investigations have been conducted to provide data on health and reproductive effects of N₂O administered in a wide array of concentrations and exposure times. Prolonged exposure to clinical concentrations has resulted in a variety of toxicologic effects in some but not all studies. In addition to the neurologic deficits described previously, these effects have included changes in growth,⁴⁸ hematopoiesis,⁴⁹ and testicular weight.⁵⁰ Similar concentrations (10% to 75% N₂O) have also been shown to cause fetal death, teratogenesis, and retarded development.^{51,52} As a recent example, Fujinaga and Baden demonstrated that 50% to 75% N₂O increased the malformation rate of embryos grown in tissue culture 11-fold (from a control value of 6%) when administered for 24 hours on a day 9 of gestation.⁵³ Fetal toxicity can be separated from the anesthetic effect per se, as equipotent concentrations of xenon do not cause such disturbances.

Of special concern to health care workers is the minimal concentration or exposure at which toxic effects can develop. Alteration in methionine synthase activity is a sensitive indicator of a biological response to N_2O . The threshold for inhibition with continuous exposure is between 500 and 1000 ppm in the rat.⁵⁵ Studies on the lowest exposure that causes toxicity have yielded mixed results. Whereas Mazze and colleagues found no adverse reproductive responses to intermittent doses of N_2O (24 hours at day 9 of gestation or 4 hours per day on days 6 through 15) in subclinical concentrations (<25%),^{56,57} Vieira et al determined that continuous exposure throughout pregnancy to 1000 ppm was associated with reduced litter size, skeletal anomalies, and prenatal growth retardation⁵⁸ and that intermittent exposure (6 hours per day 5 days per week) to 5000 ppm caused decreased litter size and a reduction in body length by day 19 of gestation.⁵⁹ Healy and colleagues reported recently that exposure to as little as 50 ppm for 5 days per week for 13 weeks resulted in decreased liver weight and leukocyte count in mice.⁶⁰ However, there was no dose-response relationship evident in these effects, and it is possible they reflected random variations. A similar study by Rice et al (4 hours exposure per day, 5 days per week for 14 weeks) found no such effects at concentrations of N_2O up to 500,000 ppm.⁶¹

Human Studies

Experimental investigations involving humans exposed to trace amounts of N_2O have concentrated on two separate issues: psychomotor performance and biochemical disturbances. Bruce et al first raised the possibility that low concentrations of N_2O could alter perceptual, cognitive, and motor skills of health care workers.⁶² They reported that inhaling N_2O at 500 ppm for 4 hours significantly impaired performance on the digit span test. Subsequently, Bruce and Bach found that 50 ppm inhaled for over 2 hours caused impairment in audiovisual performance tasks.⁶³ This last finding was instrumental in causing NIOSH to recommend 25 ppm as the standard for maximum exposure in the workplace. These findings have not been reproduced by subsequent workers.^{64,65} Cook et al⁶⁶ in particular tried to reproduce the methodology of Bruce but were still unable to detect any performance deficit with administration of trace concentrations of N_2O . In fact, concentrations over 5% were required before significant impairment was uncovered. It seems clear from the preponderance of evidence that psychomotor deficits are probably not a concern with concentrations to which a dentist could conceivably be exposed as a result of clinical practice.⁶⁷

Several investigations of health care personnel have attempted to discover biochemical alterations caused by




Figure 6. Altered dU suppression tests scores as a function of the weekly total exposure to N_2O measured by passive dosimetry. Each circle represents a single dentist subject. Shaded circles denote two subjects with altered dU suppression scores and megaloblastic changes in the bone marrow. The dotted line depicts the ACGIH recommendation of 50 ppm; the dashed line indicates 100 ppm. Data from Sweeney et al.⁷³

exposure to trace amounts of N_2O . Results have been largely negative. For instance, methionine concentrations were not altered in anesthetists chronically exposed to N_2O concentrations of 150 to 400 ppm as a consequence of their normal daily activities.⁶⁸ Similarly, analyses of neurologic function in dentists,⁶⁹ sister chromatid exchange in dental personnel,⁷⁰ sperm indices in anesthesiologists,⁷¹ and peripheral blood studies in operating room personnel⁷² revealed no significant effects of low-dose N_2O exposure. These investigations were admittedly small in scope and perhaps limited by low ambient concentrations of N_2O and insensitive methods used to detect physiological disturbances. They are collectively eclipsed by the work of Sweeney et al,⁷³ who provided the *first direct evidence that occupational exposure to N_2O can result in altered vitamin B_{12} metabolism and impaired synthesis of DNA.*

Sweeney and colleagues performed dU suppression tests and full neurological and hematological examinations on 20 dentist volunteers who routinely administered N_2O in clinical practice. Definite evidence of altered DNA synthesis in the bone marrow was obtained in two subjects, both of whom also had unequivocal, though mild, megaloblastic changes in the erythroid series. Measurements of weekly exposure to N_2O were positively associated with elevated dU suppression (Figure 6). No definite hematological or neurological findings were reported, however. It is noteworthy that these authors recommended a time-weighted average expo-

sure (TWA) of 400 ppm per anesthetic administration as being safe and reasonably obtainable with existing technology.

RECOMMENDATIONS FOR CONTROL OF OCCUPATIONAL EXPOSURE

Existing evidence indicates that a potential danger exists for adverse health effects occurring as a consequence of exposure to N_2O . There is a known mechanism by which N_2O could induce deleterious effects, and various biochemical and toxicological responses have been described in animals and humans. The evidence for danger associated with inhalation of trace amounts of N_2O is much less compelling. It would appear that some dentists and auxiliary personnel exposed to ambient N_2O may be at risk of developing biochemical disturbances that could have deleterious consequences, such as neurological deficits and miscarriage of offspring. Assuming that the toxicity of N_2O is dose-dependent and that sensitivity to N_2O is normally distributed, the preponderance of findings outlined in this review suggest that the minimum threshold for biologic effects in humans lies above both a continuous TWA of 100 ppm N_2O for an 8-hour day and a TWA of 400 ppm per anesthetic administration in the dental setting. These values are, respectively, the 100 ppm continuous exposure limit adopted in Sweden⁷⁴ and the 400 ppm limit per anesthetic administration suggested by Sweeney et al.⁷³ Clearly, the 1977 NIOSH guideline for a TWA of 25 ppm per anesthetic use is much too restrictive according to current information.⁵⁵

If 400 ppm is a reasonable TWA standard per N_2O administration in the dental office, it becomes of interest to determine what steps would be necessary to ensure compliance with that standard. Numerous investigations have shown that dental personnel are often exposed to concentrations an order of magnitude higher than 400 ppm when no attempts are made to limit N_2O pollution and/or hasten its elimination from the operator environment.^{75,76} In the Sweeney study, all but 3 of the dentists were above 400 ppm (Figure 7). With respect to an 8-hour TWA of 100 ppm, all but 6 would exceed the limit (Figure 6), assuming a 40-hour work week and a balanced daily distribution of exposure.

Under tightly controlled circumstances, the use of scavenging gas delivery systems can reduce the ambient N_2O to under 50 ppm.^{77,78} Recent surveys of occupational exposure to N_2O in dental operatories suggest, however, that practical difficulties often limit the efficacy of scavenging equipment.^{79,80} Some of these problems reflect leaks in the system or poor administration technique; others involve poor mask fit or the patient talking or exhaling orally; and still others may be inherent in the scavenging apparatus itself.⁷⁴ Periodic assessments of N_2O are essen-




Figure 7. Altered dU suppression test scores as a function of the time-weighted average exposure to N_2O per anesthetic administration. Each circle represents a single dentist subject. Shaded circles denote two subjects with altered dU suppression scores and megaloblastic changes in the bone marrow. The dotted line depicts the NIOSH recommendation of 25 ppm; the dashed line indicates 400 ppm. Data from Sweeney et al.⁷³

tial to establishing and maintaining an effective scavenging system.⁷⁷

Should the NIOSH guideline or even the less stringent ACGIH recommendation of 50 ppm be adopted by OSHA, a scavenging system removing 90% to 95% of the administered N_2O might not be sufficient to maintain occupational exposure within maximum permissible limits. Local exhaust ventilation systems hold promise for reducing N_2O pollution, but such equipment is expensive (approximately \$1000 per installation) and must encroach on the dentist's work area to be truly effective.⁸¹ An even more costly option would be to revamp the ventilation system to improve air turnover in the operator. By contrast, adoption of the standards suggested here would protect the health of exposed dental personnel while making it possible for private practitioners to achieve compliance using existing and relatively inexpensive methodologies.

REFERENCES

1. Criteria for a Recommended Standard . . . Occupational Exposure to Waste Anesthetic Gases and Vapors. DHEW (NIOSH) Publication No. 77-140, Washington, DC, US Department of Health, Education, and Welfare, 1977.
2. Jones TW, Greenfield W: Position paper of the ADA Ad Hoc Committee on Trace Anesthetics as a Potential Health Hazard in Dentistry. *JADA* 1977;95:751-756.

3. Layzer RB, Fishman RA, Schafer JA: Neuropathy following abuse of nitrous oxide. *Neurology* 1978;28:504-506.
4. Amess JAL, Burman JF, Rees GM, Nancekivell DG, Mollin DL: Megaloblastic haemopoiesis in patients receiving nitrous oxide. *Lancet* 1978;2:339-342.
5. Cohen EN, Brown BW, Wu ML, Whitcher CE, Brodsky JB, Gift HC, Greenfield W, Jones TW, Driscoll EJ: Occupational disease in dentistry and chronic exposure to trace anesthetic gases. *JADA* 1980;101:21-31.
6. Kondo H, Osborne ML, Kolhouse JF, Binder MJ, Podell ER, Utley CS, Abrams RS, Allen RH: Nitrous Oxide has multiple deleterious effects on cobalamin metabolism and causes decreases in activities of both mammalian cobalamin-dependent enzymes in rats. *J Clin Invest* 1981;67:1270-1283.
7. Skacel PO, Hewlett AM, Lewis JD, Lumb M, Nunn JF, Chanarin I: Studies on the haemopoietic toxicity of nitrous oxide in man. *Br J Haematol* 1983;53:189-200.
8. Ferstandig LL: Trace concentrations of anesthetic gases: a critical review of their disease potential. *Anesth Analg* 1978;57:328-345.
9. Vessey MP: Epidemiological studies of the occupational hazards of anaesthesia—a review. *Anaesthesia* 1978;33:430-438.
10. 1990-1991 Threshold Limit Values for Chemical Substances and Physical Agents and Biological Exposure Indices. Cincinnati, American Conference of Governmental Industrial Hygienists, 1990.
11. Lassen HCA, Henriksen E, Neukirch F, Kristensen HS: Treatment of tetanus. Severe bone-marrow depression after prolonged nitrous-oxide anaesthesia. *Lancet* 1956;1:527-530.
12. Banks RGS, Henderson JR, Pratt JM: Reactions of gases in solution. III. Some reactions of nitrous oxide with transition-metal complexes. *J Chem Soc (A)* 1968;3:2886-2890.
13. Nunn JF, Chanarin I: Nitrous oxide inactivates methionine synthetase. In: Eger EI II, ed., *Nitrous Oxide/N₂O*, New York, Elsevier Science Publishing Co., 1985.
14. Poston JM: Cobalamin-dependent formation of leucine and β -leucine by rat and human tissue. *J Biol Chem* 1980;255:10067-10072.
15. Koblin DD, Tomerson BW: Dimethylthiourea, a hydroxyl radical scavenger, impedes the inactivation of methionine synthase by nitrous oxide in mice. *Br J Anaesth* 1990;64:214-223.
16. Shane B, Stokstad ELR: Vitamin B₁₂-folate interrelationships. *Ann Rev Nutr* 1985;5:115-141.
17. Fujinaga M, Baden JM, Yhap EO, Mazze RI: Reproductive and teratogenic effects of nitrous oxide, isoflurane, and their combination in Sprague-Dawley rats. *Anesthesiology* 1987;67:960-964.
18. Bosterling B, Trudel JR, Hong K, Cohen EN: Formation of free radical intermediates during nitrous oxide metabolism by human intestinal contents. *Biochem Pharmacol* 1980;29:3037-3038.
19. Kugel G, Letelier C, Zive MA, King JC: Nitrous oxide and infertility. *Anesth Prog* 1990;37:176-180.
20. Deacon R, Lumb M, Perry J, Chanarin I, Minty B, Halsey M, Nunn J: Inactivation of methionine synthase by nitrous oxide. *Eur J Biochem* 1980;104:419-422.
21. Koblin DD, Watson JE, Deady JE, Stokstad ELR, Eger EI II: Inactivation of methionine synthetase by nitrous oxide in mice. *Anesthesiology* 1981;54:318-324.
22. Koblin DD, Waskel L, Watson JE, Stokstad ELR, Eger EI II: Nitrous oxide inactivates methionine synthetase in human liver. *Anesth Analg* 1982;61:75-78.
23. Nunn JF, Sharer NM, Gorchein A, Jones JA, Wickramasinghe SN: Megaloblastic haemopoiesis after multiple short-term exposure to nitrous oxide. *Lancet* 1982;1:1379-1381.
24. Amos RJ, Amess JAL, Hinds CJ, Mollin DL: Incidence and pathogenesis of acute megaloblastic bone-marrow change in patients receiving intensive care. *Lancet* 1982;2:835-839.
25. O'Sullivan H, Jennings F, Ward K, McCann S, Scott JM, Weir DG: Human bone marrow biochemical function and megaloblastic hematopoiesis after nitrous oxide anesthesia. *Anesthesiology* 1981;55:645-649.
26. Nunn JF, Chanarin I, Tanner AG, Owen ERTC: Megaloblastic bone marrow changes after repeated nitrous oxide anaesthesia: reversal with folic acid. *Br J Anaesth* 1986;58:1469-1470.
27. Crawford JS, Lewis M: Nitrous oxide in early pregnancy. *Anaesthesia* 1986;41:900-905.
28. Nunn JF, O'Morain C: Nitrous oxide decreases motility of human neutrophils in vitro. *Anesthesiology* 1982;45:45-48.
29. Davy H: *Researches, Chemical and Philosophical; Chiefly Concerning Nitrous Oxide, or Dephlogisticated Nitrous Air, and Its Respiration.* (Facsimile of 1800 ed.) London, Butterworths, 1977.
30. DiMaio VJM, Garriott JC: Four deaths resulting from abuse of nitrous oxide. *J Forensic Sci* 1978;23:169-172.
31. Suruda AJ, McGlothlin JD: Fatal abuse of nitrous oxide in the workplace. *J Occup Med* 1990;32:682-684.
32. Murray MJ, Murray WJ: Nitrous oxide availability. *J Clin Pharmacol* 1980;20:202-205.
33. Layzer RB: Myeloneuropathy after prolonged exposure to nitrous oxide. *Lancet* 1978;2:1227-1230.
34. Wood RW, Grubman JU, Weiss B: Nitrous oxide self-administration by the squirrel monkey. *J Pharmacol Exp Ther* 1977;202:491-499.
35. Dinn JJ, Weir DG, McCann S, Reed B, Wilson P, Scott JM: Methyl group deficiency in nerve tissue: a hypothesis to explain the lesion of subacute combined degeneration. *Irish J Med Sci* 1980;149:1-4.
36. Weir DG, Keating S, Molloy A, McPartlin J, Kennedy S, Blanchflower J, Kennedy DG, Rice D, Scott JM: Methylation deficiency causes vitamin B₁₂-associated neuropathy in the pig. *J Neurochem* 1988;51:1949-1952.
37. van der Westhuyzen J, Fernandes-Costa F, Metz J: Cobalamin inactivation by nitrous oxide produces severe neurological impairment in fruit bats: protection by methionine and aggravation by folates. *Life Sci* 1982;31:2001-2010.
38. Deacon R, Purkiss P, Green R, Lumb M, Perry J, Chanarin I: Vitamin B₁₂ neuropathy is not due to failure to methylate myelin basic protein. *J Neurol Sci* 1986;72:113-117.
39. Rosenberg H, Orkin FK, Springstead J: Abuse of nitrous oxide. *Anesth Analg* 1979;58:104-106.
40. Gutmann L, Johnsen D: Nitrous oxide-induced myeloneuropathy: report of cases. *JADA* 1981;103:239-241.
41. Vaisman AI: Working conditions in surgery and their effect on the health of anesthesiologists (in Russian). *Eksp Khir Anesteziol* 1967;3:44-49.
42. Brodsky JB, Cohen EN, Brown BW Jr, Wu ML, Whitcher CE: Exposure to nitrous oxide and neurologic disease among dental professionals. *Anesth Analg* 1981;60:297-301.

43. Brodsky JB: Toxicity of nitrous oxide. In: Eger EI II, ed: Nitrous Oxide/N₂O, New York, Elsevier Science Publishing Co., 1985.
44. Spence AA: Environmental pollution by inhalation anaesthetics. *Br J Anaesth* 1987;59:96-103.
45. Tannenbaum TN, Goldberg RJ: Exposure to anaesthetic gases and reproductive outcome. A review of epidemiologic literature. *J Occup Med* 1985;27:659-668.
46. Ericson HA, Källén AJB: Hospitalization for miscarriage and delivery outcome among Swedish nurses working in operating rooms 1973-1978. *Anesth Analg* 1985;64:981-988.
47. Hemminki K, Kyyrönen P, Lindbohm M-L: Spontaneous abortions and malformation in the offspring of nurses exposed to anaesthetic gases, cytostatic drugs, and other potential hazards in hospitals based on registered information of outcome. *J Epidemiol Community Health* 1985;39:141-147.
48. Rice SA, Mazze RI, Baden JM: Effects of subchronic intermittent exposure to nitrous oxide in Swiss Webster mice. *J Environ Pathol Toxicol Oncol* 1985;6:271-282.
49. Green CD, Eastwood DN: Effects of N₂O inhalation on hemopoiesis in rats. *Anesthesiology* 1963;24:341-345.
50. Kripke BJ, Kelman AD, Shah NK, Balough K, Handler AH: Testicular reaction to prolonged exposure to N₂O. *Anesthesiology* 1976;44:104-113.
51. Fink BR, Shepard TH, Blandau RJ: Teratogenic activity of nitrous oxide. *Nature* 1967;214:146-148.
52. Ramazzotto LJ, Carlin RD, Warchalowski GA: Effects of nitrous oxide during organogenesis in the rat. *J Dent Res* 1979;58:1940-1943.
53. Fujinaga M, Baden JM: Effects of nitrous oxide on rat embryos grown in culture. *Anesthesiology* 1989;71:991-992.
54. Lane GA, Nahrwold ML, Tait AR, Taylor-Busch M, Cohen PJ: Anaesthetics as teratogens: nitrous oxide is fetotoxic, xenon is not. *Science* 1980;210:899-901.
55. Sharer NM, Nunn JF, Royston JP, Chanarin I: Effects of chronic exposure to nitrous oxide on methionine synthetase activity. *Br J Anaesth* 1983;55:693-700.
56. Mazze RI, Wilson AI, Rice SA, Baden JM: Reproduction and fetal development in mice chronically exposed to nitrous oxide. *Teratology* 1982;26:11-16.
57. Mazze RI, Wilson AI, Rice SA, Baden JM: Reproduction and fetal development in rats exposed to nitrous oxide. *Teratology* 1984;30:259-265.
58. Vieira E, Cleaton-Jones P, Austin JC, Moyes DG, Shaw R: Effects of low concentrations of nitrous oxide on rat fetuses. *Anesth Analg* 1980;59:175-177.
59. Vieira E, Cleaton-Jones P, Moyes D: Effects of low intermittent concentrations of nitrous oxide on the developing rat fetus. *Br J Anaesth* 1983;55:67-69.
60. Healy CE, Drown DB, Sharma RP: Short term toxicity of nitrous oxide on the immune, hemopoietic and endocrine systems in CD-1 mice. *Toxicol Ind Health* 1990;6:57-70.
61. Rice SA, Mazze RI, Baden JM: Effects of subchronic intermittent exposure to nitrous oxide in Swiss Webster mice. *J Environ Pathol Toxicol Oncol* 1985;6:271-282.
62. Bruce DL, Bach MJ, Arbit J: Trace anesthetic effects on perceptual, cognitive, and motor skills. *Anesthesiology* 1974;40:453-458.
63. Bruce DL, Bach MJ: Trace Effects of Anesthetic Gases on Behavioral Performance of Operating Room Personnel, HEW Publication No. (NIOSH) 76-169. Cincinnati, US Department of Health, Education and Welfare, 1976.
64. Smith G, Shirley AW: Failure to demonstrate effect of trace concentrations of nitrous oxide and halothane on psychomotor performance. *Br J Anaesth* 1977;49:65-70.
65. Frankhuizen JL, Vlek CAJ, Burm AGL, Reijger V: Failure to replicate negative effects of trace anaesthetics on mental performance. *Br J Anaesth* 1978;50:229-234.
66. Cook TL, Smith M, Starkweather JA, Winter PM, Eger EI II: Behavioral effects of trace and subanesthetic halothane and nitrous oxide in man. *Anesthesiology* 1978;49:419-424.
67. Smith G, Shirley AW: A review of the effects of trace concentrations of anaesthetics on performance. *Br J Anaesth* 1978;50:701-712.
68. Nunn JF, Sharer N, Royston D, Watts RWE, Purkiss P, Worth HG: Serum methionine and hepatic enzyme activity in anaesthetists exposed to nitrous oxide. *Br J Anaesth* 1982;54:593-597.
69. Dyck PJ, Grina LA, Lambert EH, Calder CS, Oviatt K, Rehder K, Lund BA, Skau KA: Nitrous oxide neurotoxicity studies in man and rat. *Anesthesiology* 1980;53:205-209.
70. Husum B, Wulf HC, Mathiassen F, Niebuhr E: Sister chromatid exchanges in lymphocytes of dentists and chairside assistants: no indication of a mutagenic effect of exposure to waste nitrous oxide. *Community Dent Oral Epidemiol* 1986;14:148-151.
71. Wyrobek AJ, Brodsky J, Gordon L, Moore DH II, Watchmaker G, Cohen EN: Sperm studies in anesthesiologists. *Anesthesiology* 1981;55:527-532.
72. Salo M, Rajamäki A, Nikoskelainen J: Absence of signs of vitamin B₁₂-nitrous oxide interaction in operating theatre personnel. *Acta Anaesthesiol Scand* 1984;28:106-108.
73. Sweeney B, Bingham RM, Amos RJ, Petty AC, Cole PV: Toxicity of bone marrow in dentists exposed to nitrous oxide. *Br Med J* 1985;291:567-569.
74. Hallonsten A-L: Nitrous oxide scavenging in dental surgery. I. A comparison of the efficiency of different scavenging devices. *Swed Dent J* 1982;6:203-213.
75. Millard RI, Corbett TH: Nitrous oxide concentrations in the dental operator. *J Oral Surg* 1974;32:593-594.
76. Hillman KM, Saloojee Y, Brett II, Cole PV: Nitrous oxide concentrations in the dental surgery. *Anaesthesia* 1981;36:257-262.
77. Whitcher CE, Zimmerman DC, Tonn EM, Piziali RL: Control of occupational exposure to nitrous oxide in the dental operator. *JADA* 1977;95:763-776.
78. Donaldson D, Orr J: A comparison of the effectiveness of nitrous oxide scavenging devices. *J Can Dent Assoc* 1989;55:535-537.
79. Ship JA: A survey of nitrous oxide levels in dental offices. *Arch Environ Health* 1987;42:310-314.
80. Middendorf PJ, Jacobs DE, Smith KA, Mastro DM: Occupational exposure to nitrous oxide in dental operatories. *Anesth Prog* 1986;33:91-97.
81. Jacobs DE, Middendorf PJ: Control of nitrous oxide exposures in dental operatories using local exhaust ventilation: a pilot study. *Anesth Prog* 1986;33:235-242.